Listen Here

| |

Actionable
Takeaways

Target customers facing existential financial pressure, not optimal market conditions:

Shadowbox entered through lab diagnostics—a commoditized, low-margin segment hemorrhaging money where providers faced $5K-$50K integration costs per connection taking 3-6 months. Greg acknowledged labs are "the redheaded stepchild of healthcare" but their desperation made them willing to pilot unproven technology. The lesson: segments with severe unit economics problems become early adopter pools because status quo costs exceed perceived risk of new vendors.

Build a partnerships function before you have market leverage:

Shadowbox hired a partnerships-focused employee early to cultivate relationships with RCM vendors and lab information system providers already selling to target customers. Rather than waiting for customer traction to attract partners, they used partnerships to generate initial traction. Greg emphasized healthcare adoption requires credible references—partnerships provide instant credibility entrepreneurs can't buy. Map your ecosystem's existing vendor relationships and pursue co-sell arrangements before achieving meaningful ARR.

Use early customer feedback to migrate upmarket, not pivot laterally:

Shadowbox started with labs, expanded to imaging centers, but their true ICP emerged as health systems with 500-1,000 community providers on disparate EHRs where traditional integration economics break down. Greg noted: "health systems that have major outreach programs where it doesn't pencil out to have them on their EPIC system." The migration path moved from small, desperate customers toward larger organizations facing the same core problem at scale. Don't mistake initial ICP for ultimate ICP—use early segments as beachheads to validate technology before pursuing customers with better economics.

Partner with horizontal competitors when you solve orthogonal use cases:

The HC1 deal splits the interoperability market—structured, predictable integrations go to HC1's traditional approach while rapid deployments to fragmented provider networks go to Shadowbox. This isn't channel partnership but market segmentation by use case economics. Greg explained they bring "something complementary to and in some ways competitive" but combined create offerings competitors can't match. Evaluate whether your "competitors" actually serve different jobs-to-be-done within the same category, then structure partnerships around use case delineation rather than territorial splits.

Leverage policy expertise as product moat in regulated markets:

Greg's Capitol Hill background enabled Shadowbox to support the Coalition for Innovative Lab Testing's successful lawsuit blocking FDA regulation of lab-developed tests—directly protecting their customers' business models. This wasn't marketing but strategic positioning that demonstrates commitment beyond vendor relationships. In heavily regulated industries, founders with policy expertise or advisors who can shape regulatory outcomes create defensibility that pure technology cannot. Consider how industry advocacy amplifies customer loyalty while potentially expanding TAM through favorable regulatory changes.

Conversation
Highlights

 

How Shadowbox Turned Healthcare’s Least Profitable Segment Into a $950B Market Entry Point

Healthcare providers waste nearly $1 trillion annually on manual processes—not $300 billion as commonly cited, but $950 billion according to testimony before the U.S. Senate. The problem isn’t workflow inefficiency. It’s infrastructure economics: accessing siloed EHR data costs $5,000 to $50,000 per integration and takes three to six months to implement.

In our recent episode of Category Visionaries, Gregory Stein, CEO of Shadowbox, explained how his company built patented browser technology that accesses the document object model and API endpoints within EHR systems, enabling integration in five minutes rather than months. But the more instructive story is how they went to market in a system designed to resist exactly what they’re selling.

 

Targeting Financial Desperation Instead of Buying Power

In 2017, Shadowbox had validated technology and multiple potential segments to pursue. Gregory chose laboratory diagnostics—the segment every other vendor avoids.

“The lab industry is like the most volatile,” Gregory explains. “They go in and out of business, they have terrible margin. It’s sort of the, you know, to use a pejorative term, the redheaded stepchild, if you will, of the healthcare system. Nobody likes lab. They’re always first one to go.”

The calculation was deliberate. Labs couldn’t afford $5,000-$50,000 integrations with 3-6 month timelines. Their unit economics were so broken that maintaining the status quo threatened their survival. Gregory recognized that “because labs are under such financial duress and such challenge from insurance companies, they were willing to take a flyer on an unproven technology with an unproven leader.”

This inverts conventional market entry logic. Standard wisdom says target segments with healthy margins and established budgets. Shadowbox targeted customers where the pain of doing nothing exceeded the perceived risk of adopting unproven technology from an unknown vendor.

The lesson isn’t “target unprofitable segments.” It’s understanding when dire unit economics create adoption windows that don’t exist in healthier markets. The key variable is whether your solution addresses the specific financial constraint causing the desperation.

 

First-Touch Product Validation

Shadowbox launched their first customer in 2018. When the medical assistant responsible for ordering tests hit the button labeled “order now,” the form auto-populated with patient data extracted from the EHR through Shadowbox’s browser.

“Her face just lit up and she said, this is going to save me so much time,” Gregory recalls. “Because otherwise I’m filling out either on paper and if it’s wrong, then I’m getting phone calls from the lab and it’s just a huge hassle.”

That interaction validated more than technical functionality. It confirmed that value was immediately visible without explanation, the alternative was painful enough that adoption required no persuasion, and the improvement was dramatic enough to create instant advocacy.

 

Building Partnership Infrastructure Pre-Traction

Most startups pursue partnerships after establishing market presence. Shadowbox hired for partnerships as an early function—before they had leverage to offer potential partners.

The target: revenue cycle management vendors and lab information system providers already selling to Shadowbox’s ICP. These partners faced the same integration economics problem. When prospects couldn’t afford traditional integrations, partners could position Shadowbox as an alternative deployment path.

“Getting your foot in the door with a credible partner as a reference is probably the most important thing in healthcare,” Gregory emphasizes. “Healthcare is one of the slowest to adopt industries out there.”

The strategy created a distribution mechanism before Shadowbox had the brand recognition or customer base to generate meaningful inbound volume. Partners provided both customer access and category credibility simultaneously.

 

Using Unprofitable Segments as Technology Beachheads

Labs validated Shadowbox’s core technology and generated initial revenue. But Gregory recognized the ultimate ICP differed significantly: “The true ICP, I think, ultimately are health systems that have major outreach programs where they have hundreds if not thousands of community providers, where it doesn’t pencil out to have them on their EPIC system or their Oracle server system.”

This articulates the beachhead-to-expansion path clearly. Labs had the same core problem—fragmented EHR access—but lacked resources for traditional solutions. Health systems have the same problem at dramatically larger scale: 500 to 1,000 community providers on disparate EHR systems where traditional integration would cost millions and require years to implement.

Shadowbox moved from labs to imaging centers, progressively building toward health systems. Each segment provided validation for entering the next tier. The technology that worked for resource-constrained labs could handle enterprise-scale provider network complexity.

 

Market Segmentation Through Use Case Economics

In July, Shadowbox announced a partnership with HC1, a company approximately five to six times their size that serves roughly 20% of U.S. health systems. HC1 provides traditional interoperability through HL7 and API integrations—ostensibly competitive with Shadowbox’s approach.

The partnership functions because they solve orthogonal use case economics. “We’re able to split the market, if you will, in terms of use cases that rely or require an HL7 integration or API,” Gregory explains. “That goes to HC1, and then those that where that doesn’t pencil out, those go to Shadowbox.”

This isn’t channel partnership or geographic territory division. It’s market segmentation based on integration economics profiles. Structured, predictable integrations where the ROI of custom development pencils out go to HC1’s traditional approach. Rapid deployments to fragmented provider networks where traditional integration economics break down go to Shadowbox.

Combined, they address use cases neither could serve independently. “Other competitors of ours, if you will, in our marketplace can’t offer what we’re offering as a combined thing,” Gregory notes.

The partnership also solves the credibility problem. HC1’s existing health system relationships provide access and validation that Shadowbox couldn’t generate independently at their stage.

 

Regulatory Positioning as Competitive Moat

Gregory’s background as a congressional staffer on Capitol Hill became an unexpected source of competitive advantage. He’s engaged with members of Congress, relevant committees, and the administration regarding expansion of information blocking provisions in the 21st Century Cures Act.

More significantly, Shadowbox supported the Coalition for Innovative Lab Testing’s lawsuit that successfully blocked FDA regulation of lab-developed tests as medical devices.

“That shows that we aren’t in it just for our own technology, our own company, our own customer, our own revenue,” Gregory says. “We’re in it for the industry and we supported it.”

This creates customer loyalty that transcends typical vendor relationships. Shadowbox isn’t merely solving a technical integration problem—they’re protecting their customers’ business models at the regulatory level. In heavily regulated industries, policy expertise and advocacy create defensibility that technology alone cannot provide.

The principle extends beyond healthcare. In any regulated market, founders with policy fluency or advisors who can influence regulatory outcomes create moats that competitors focused purely on product cannot replicate.

 

Where They Stand

Today, Shadowbox processes thousands of transactions daily across thousands of users. Gregory estimates they’re at 25-30% technology maturity but only 0.5% market penetration.

The vision: “Shadowbox will become the enterprise browser of choice for healthcare, meaning every single desktop laptop has a Shadowbox on it.” At scale, any healthcare provider could instantly integrate with any vendor or service through the Shadowbox browser without custom integration work.

The path from desperate labs to enterprise healthcare browser required unconventional decisions at each inflection point. Target segments others systematically avoid. Build partnership infrastructure before you have negotiating leverage. Use early segments as technology beachheads rather than final destinations. Partner with competitors when you address different use case economics within the same category. Deploy policy expertise as competitive moat in regulated markets.

These strategies don’t appear in standard B2B playbooks because they’re predicated on specific market conditions: broken unit economics creating adoption windows, slow-moving incumbents creating partnership opportunities, and regulatory complexity creating defensibility beyond product. But for founders facing similar constraints, Shadowbox’s path demonstrates how the segments and strategies that appear least attractive often provide the fastest route to validating technology that can eventually capture significantly larger markets.

 

Recommended Founder
Interviews

Ignacio Medrano

Founder & CMO of Savana

Ignacio Medrano, Founder & CMO of Savana: $44M Raised to Transform Healthcare Intelligence Through AI

Ben Albert

CEO & Co-Founder of Upfront Healthcare

Ben Albert, CEO & Co-Founder of Upfront Healthcare: $30 Million Raised to Power the Future of Patient Engagement

Veer Gidwaney

CEO & Founder of Ansel Health

Veer Gidwaney, CEO & Founder of Ansel Health: $50 Million Raised to Transform Supplemental Health Insurance

Mike Desjadon

CEO of Anomaly

Why Anomaly avoids annual curiosity revenue (ACR) — and you probably should to | Mike Desjadon ($30M Raised)

Alex Zekoff

CEO and Co-Founder of Thoughtful AI

Alex Zekoff, CEO and Co-Founder of Thoughtful AI: $21 Million Raised to Power the Future of Healthcare Automation

Ty Allen

CEO of SocialClimb

Ty Allen, CEO of SocialClimb: $12 Million Raised to Power the Future of Healthcare Marketing

Dr Thomas Oakley

CEO of Feedback PLC

Dr Thomas Oakley, CEO of Feedback PLC: £20 Million Raised to Build the Future of Patient Data Sharing

Rafid Fadul

CEO and Co-Founder of Zivian Health

Rafid Fadul, CEO and Co-Founder of Zivian Health: $3 Million Raised to Power the Future of Compliant Healthcare Collaborations

Andreas Cleve

CEO and Co-Founder of Corti

Andreas Cleve, CEO and Co-Founder of Corti: $32 Million Raised to Power the Future of Patient Consultations

Alfred Griffin

CEO and Co-Founder of CEO and Co-Founder

Alfred Griffin, CEO and Co-Founder of LightForce: $150 Million Raised to Power the Future of Orthodontics

Omer Maman

VP of Marketing of Healthee

Why AI Should Enhance, Not Replace Your Marketing Team

Cody Simmons

CEO of DermaSensor

Cody Simmons, CEO of DermaSensor: $36 Million Raised to Build the First AI-Powered Skin Cancer Detection Tool for Primary Care

Kevin Flyangolts

CEO and Founder of Aclid

Kevin Flyangolts, CEO & Founder of Aclid: $4 Million Raised to Build the Future of Biosecurity

Viral Patel

Founder and CEO of Radish Health

Viral Patel, CEO of Radish Health: $5 Million Raised to Connect Employees with a Better Healthcare Experience

Vicky Demas

CEO of Identifeye Health

Vicky Demas, CEO of identifeye HEALTH: $90 Million Raised to Power the Future of Retinal Imaging

Daniel Lambert

CEO of PathologyWatch

Daniel Lambert, CEO of PathologyWatch: Over $50 Million Raised to Build the Future of Digital Pathology

Dilpreet Sahota

CEO of Trek Health

Dilpreet Sahota, CEO of Trek Health: $3 Million Raised to Help Mental Health Providers Accept Insurance

Rishi Nayyar

CEO and Co-Founder of PocketHealth

Rishi Nayyar, CEO and Co-Founder of PocketHealth: $22.5 Million Raised to Power the Future of Medical Image Sharing

Michael Passanante

Senior Vice President of Marketing and Communications of Capital Rx

How to Build 18-Month Attribution Models That Actually Work

Verena Gerhardus

Director of Growth of Nelly Solutions

How Nelly Grew 3X Through Meta Ads in Health Tech

Cesar Herrera

CEO and Co-Founder of Yuvo Health

Cesar Herrera, CEO and Co-Founder of Yuvo Health: $28 Million Raised to Revolutionize Healthcare Access

Dimitrios Skaltsas

CEO & Co-Founder of Intelligencia AI

Dimitrios Skaltsas, CEO & Co-Founder of Intelligencia AI: $15.5 Million Raised to Build the Future of Drug Development

Corey Washington

Senior Marketing Manager of Amenities Health

Humanizing Healthcare Tech: Marketing Lessons from Amenities

Angella Gronenthal

VP of Marketing of Nice Healthcare

Joe Gagnon

CEO of 1upHealth

Joe Gagnon, CEO at 1upHealth: Over $75 Million Raised to Build the Future of Healthcare Data

Jennifer Bittinger

President and Founder of Narrativa

How Narrativa leveraged COVID-19 as a market catalyst to accelerate AI adoption in pharma | Jennifer Bittinger ($2.4M Raised)

Kristen Valdes

CEO & Founder of B.well

Kristen Valdes, CEO & Founder of B.well: $100 Million Raised to Reimagine the Healthcare Experience

Henry O’Connell

CEO & Founder of Canary Speech

Henry O’Connell, CEO & Founder of Canary Speech: $26 Million Raised to Build the Future of Vocal Biomarker Technology

Aasim Saeed

CEO and Founder of Amenities Health

Aasim Saeed, CEO and Founder of Amenities Health: $10 Million Raised to Build the Future of Patient Engagement

Nabeel Kaukab

Founder and CEO of Phamily

How Phamily built an eight-figure ARR healthcare company without discounting: The subsidized R&D approach | Nabeel Kaukab ($25M Raised)

Amy Brown

CEO and Founder of Authenticx

Amy Brown, CEO and Founder of Authenticx: $28 Million Raised to Build the Future of Listening AI

Amar Kendale

President and Co-Founder of Homeward

Amar Kendale, President & Co-Founder of Homeward: $70 Million Raised to Transform Rural Healthcare Through Technology

Austin McChord

CEO of Casana

Austin McChord, CEO of Casana: Over $46 Million Raised to Create the Future of In-Home Health Monitoring

Senan Ebrahim

CEO & Founder of Delfina

Senan Ebrahim, CEO & Founder of Delfina: $10 Million Raised to Build the Future of Intelligent Pregnancy Care

Jocelyn Nowak

Marketing & Sales Enablement Lead of FIGUR8

Integrity-Driven Marketing: FIGUR8’s Path to 3,000+ Clinics

Brad Kittredge

CEO & Co-Founder of Brightside

Brad Kittredge, CEO & Co-Founder of Brightside: $150 Million Raised to Build the Future of Mental Healthcare

Samson Magid

Co-Founder and CEO of HealthSnap

Samson Magid, Co-Founder and CEO of HealthSnap: Over $12 Million Raised to Build the Future of Remote Patient Monitoring

Michael Chang

Mastering Market Fit in AI: Insights from Michael Chang, Director of Marketing at ArteraAI

Michael Gorton

Founder of Teladoc

Teladoc Founder Michael Gorton on the Early Days of Pioneering the Telemedicine Category (And What’s He’s Up to Next)

James Bates

CEO and Founder of AdviNOW Medical

James Bates, CEO and Founder of AdviNOW Medical: $24 Million Raised to Build the Future of AI-Powered Healthcare

Stacy Edgar

CEO and Co-Founder of Venteur

Stacy Edgar, CEO & Co-Founder of Venteur: $7.6 Million Raised to Build the Future of Health Insurance

Elad Ferber

CEO & Co-Founder of Synthpop

Elad Ferber, CEO & Co-Founder of Synthpop: $8 Million Raised to Build the Future of Healthcare Administration with AI

Kourosh Davarpanah

Co-Founder and CEO of Inato

Kourosh Davarpanah, Co-Founder and CEO of Inato: Over $35 Million Raised to Build the Future of Clinical Trials

Trenor Williams

CEO and Co-Founder of Socially Determined

Trenor Williams, CEO and Co-Founder of Socially Determined: $34 Million Raised to Build the Social Risk Intelligence Category

Derek Streat

Co-Founder & Chief Executive Officer of Dexcare

Derek Streat, CEO of Dexcare: $110 Million Raised to Help Health Systems to Find Time for the Best Care

Mark Lehmkuhle

CEO & Founder of Epitel

Mark Lehmkuhle, CEO & Founder of Epitel: $20 Million Raised to Build the Future of Brain Health Monitoring

Trey Sutten

CEO & Co-Founder of Siftwell Analytics

Trey Sutten, CEO & Co-Founder of Siftwell Analytics: $5 Million Raised to Transform Healthcare Analytics with AI-Powered Predictions

Khaled Boukadoum

Founder of Torch Dental

Khaled Boukadoum, Founder of Torch Dental: $49.5 Million Raised to Transform Dental Supply Management Through Digital Innovation

Itzik Cohen

Co-Founder and CEO of PayZen

Itzik Cohen, Co-Founder and CEO of PayZen: $240 Million Raised to Build the Future of Affordable Health Care

Torben Nielsen

CEO & Co-Founder of Uptiv Health

Torben Nielsen, CEO of Uptiv Health: $7.5M Raised to Build the Future of Infusion Therapy Through Technology-Enabled Retail Centers

Justin Dearborn

Founder & CEO of Praia Health

Justin Dearborn, Founder & CEO of Praia Health: $20 Million Raised to Build the Future of Consumer Experience in Healthcare

Joshua Miller

CEO and Co-Founder of Gradient Health

Joshua Miller, CEO & Co-Founder of Gradient Health: $5.7 Million Raised to Build the Future of Medical Imaging

Richard Queen

CEO and Co-Founder of DignifiHealth

Richard Queen, CEO and Co-Founder of DignifiHealth: $7 Million Raised to Drive Better Patient Outcomes in Rural Healthcare and Beyond

Matthew Stoudt

CEO and Founder of AppliedVR

Matthew Stoudt, CEO and Founder of AppliedVR: Over $70 Million Raised to Build the Future of Chronic Pain Relief

David King Lassman

Founder of GigXR

David King Lassman, Founder of GigXR: $7 Million Raised to Bring Immersive Learning to Healthcare

Alexandra Ferraro

Head of Marketing of Intelligencia AI

Beyond Perfect: Healthcare Tech Marketing That Drives Real Revenue

Brett Kleger

CEO of Datacubed Health

Brett Kleger, CEO of Datacubed Health: $43 Million Raised to Revolutionize Clinical Trial Data Collection

Teodor Grantcharov

Founder of Surgical Safety Technologies Inc.

How Surgical Safety Technologies targeted the most challenging customers first (massive hospitals) | Teodor Grantcharov

Kyle Kiser

CEO of Arrive Health

Kyle Kiser, CEO of Arrive Health: Over $40 Million Raised to Improve the Value of Healthcare Through Informed Decision-Making

Matt Renfro

Co-Founder & CEO of Lynx

Matt Renfro, CEO of Lynx: $17.5 Million raised to Bring Modern Fintech to Healthcare

Nick Soman

CEO & Founder of Decent

Nick Soman, CEO & Founder of Decent: $43 Million Raised to Build the Future of Direct Primary Care

David Berry

CEO and Founder of Valo

David Berry, CEO and Founder of Valo: Over $500 Million Raised to Build the Future of Drug Discovery

Brock Leonti

CEO & Co-Founder of Prescribe FIT

Brock Leonti, CEO & Co-Founder of Prescribe FIT: $15 Million Raised to Build the Future of Orthopedic Care

Joseph Schneier

CEO of Trusty Care

Joseph Schneier, CEO of Trusty Care: $13+ Million Raised to Shape the Future of Medicare

Daniel West

CEO of Prospection

Daniel West, CEO of Prospection: $36 Million Raised to Build the Future of Patient-Centric Intelligence

Armon Sharei

CEO & Founder of Portal

Armon Sharei, CEO & Founder of Portal: $5 Million Raised to Power the Future of Cell Engineering

Todd Zion

Founder of Akston Biosciences

Todd Zion, Founder of Akston Biosciences: From a $500M Exit to Pioneering Biotech Innovation in Pet Health

Dr. Nan-Wei Gong

CEO and Founder of FIGUR8

Dr. Nan-Wei Gong, CEO & Founder of FIGUR8: $40 Million Raised to Build the Future of Musculoskeletal Health and Injury Data Solutions

Thomas Knox

CEO & Founder of VitVio

Thomas Knox, CEO & Founder of VitVio: $10 Million Raised to Transform Surgical Operations Through AI-Powered Automation

Danny Freed

CEO & Founder of Blueprint

Danny Freed, CEO & Founder of Blueprint: $13.7 Million Raised to Build the Future of Therapist Enablement

Dipanwita Das

CEO and Co-Founder of Sorcero

Dipanwita Das, CEO and Co-Founder of Sorcero: Over $20 Million Raised to Power Medical Affairs Teams of the Future

Marshall Darr

CEO & Co-Founder of StretchDollar

How StretchDollar drives leads from LLM search | Marshall Darr

Hala Borno

Founder and CEO of Trial Library

Hala Borno, Founder and CEO of Trial Library: $5M Raised to Improve Patient Recruitment and Diversity in Oncology Clinical Trials